معرفی
Ulrika Rosenström serves as a Senior Lecturer in the Department of Medicinal Chemistry at Uppsala University, where she conducts research in radiopharmaceutical chemistry and molecular imaging. Her work focuses on developing novel radiotracers for cancer diagnostics and therapeutics, with particular emphasis on prostate cancer imaging and treatment.
Dr. Rosenström's research interests span multiple areas of radiopharmaceutical development, including molecular design of peptide-based imaging agents, optimization of radiolabeling techniques, and evaluation of biodistribution properties. Her work bridges medicinal chemistry with clinical applications, particularly in the development of PSMA and GRPR-targeted agents for prostate cancer. She has made significant contributions to understanding how molecular modifications affect tracer performance in vivo, with applications in both diagnostic imaging and targeted radiotherapy.
Analysis of her publication record reveals a strong focus on translational research, with numerous preclinical studies designed to advance radiopharmaceuticals toward clinical application. Her work demonstrates expertise in multiple radiolabeling techniques (including Ga-68, Tc-99m, and Lu-177) and spans various molecular targets relevant to oncology and fibrosis imaging. Recent publications show continued innovation in linker design, radiometal selection, and optimization of pharmacokinetic properties.
Dr. Rosenström has received recognition through multiple patent citations and substantial academic readership across her publications, indicating her work's impact in the field of nuclear medicine and molecular imaging.
Her collaborative research approach is evident through extensive co-authorship with colleagues across Uppsala University and international institutions. She has supervised numerous research projects focused on radiopharmaceutical development, contributing to the education and training of future scientists in this specialized field.
